Effect of uroacitides in improving quality of life of advanced cancer patients
Abstract：AIM: To evaluate the influences of uroacitides on the quality of life(QOL) in 135 cases of advanced cancer patients and value of clinical application . METHODS: The quality of patients life were also questioned and evaluated using the Chinese version of QLQ C 30 developed the European Organization for Research and Treatment of Cancer (EORTC).This study was designed as a multi center,non randomized open clinical study at 12 different hospitals. Uroacitides was administered as a single agent in a dosage of 300 ml through the deep vein catheter.The 135 patients entered into the study were treated with uroacitides once a day for 4 8 weeks.The clinical benefits(KPS,pain,body,weight,symptoms)and the quality of life were questionnaire survey in 135 patients before and after 2,4,6,8 weeks treatments with uroacitides. RESULTS:The median response rate for 15 scales of EORTC QLQ C 30 was 44.5% among 135 patients.The medians response rates were 52.9% , 37.0% , 42.1% , 50.0% , 35.8% , 37.5% and 33.3% ,respectively in the patients with primary liver cancer,non small cell lung cancer,colorectal cancer,breast cancer,gastric cancer,esophageal cancer and brain tumor. CONCLUSION: Uroacitides can improve the quality of life significantly in advanced cancer patients and have clinical treatment value.
Machine-generated Keywords：
Publication Date：2004-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：2( 384-385 )